A few weeks after filing eplontersen with regulators in the US, AstraZeneca PLC and Ionis Pharmaceuticals, Inc. have presented positive long-term data for the transthyretin amyloidosis (ATTR) therapy.
At the beginning of March, the companies filed eplontersen with the US Food and Drug Administration for patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) on the back of 35-week interim data from the Phase III NEURO-TTRansform trial
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?